Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       
 
 

Biotechnology, 36  Ticker: FHKZRX
 
Description
A unit investment trust that seeks to provide above average capital appreciation by investing in a concentrated portfolio of biotechnology related companies.
 
Summary
Product Code: BTGR36
Portfolio Status: Secondary
Initial Offer Date: 03/29/2017
Secondary Date: 06/26/2017
Portfolio Ending Date: 03/29/2019
Tax Structure: Regulated Investment Company
Distributions: Semi-Annual
 
Initial Offer Price: $10.0000
NAV(*): $10.2912
POP(*): $10.6589
Remaining Deferred Sales Charge: $0.1634
* As of Trade Date: 07/19/2017 4:00pm ET
The Public Offering Price (POP) represents the net asset value per unit plus any applicable organization costs and sales charges. The Net Asset Value (NAV) represents the value per unit of a trust’s portfolio securities and other assets reduced by applicable deferred sales charges and other liabilities.

 Estimated Net Annual Distribution Per Unit
Estimated Net Annual Distribution * $0.0434
Subsequent Years * $0.0433
As of 07/17/2017
* The estimated net annual distribution for subsequent years is expected to be less than the amount for the first year because a portion of the securities included in the portfolio will be sold to pay for organization costs, the deferred sales charge and the creation and development fee.  The estimates are based on annualizing the most recent dividends declared by the issuers of the securities included in the portfolio. There is no guarantee that the issuers of the securities included in the portfolio will declare distributions in the future or that, if declared, they will either remain at current levels or increase over time.

 Holdings Analysis Click here to Perform a Benchmark Comparison  
 Sector Weighting
Consumer Discretionary  Consumer Discretionary 0.00%
Consumer Staples  Consumer Staples 0.00%
Energy  Energy 0.00%
Financials  Financials 0.00%
Health Care  Health Care 99.93%
Industrials  Industrials 0.00%
Information Technology  Information Technology 0.00%
Materials  Materials 0.00%
Real Estate  Real Estate 0.00%
Telecommunication Services  Telecommunication Services 0.00%
Utilities  Utilities 0.00%
Other  Other 0.07%
 
  Large Mid Small  
Growth  50.33% 19.20% 8.17%  
Value  11.60% 7.76% 2.87%  

 Style Weighting
Large-Cap Growth 50.33%
Large-Cap Value 11.60%
Mid-Cap Growth 19.20%
Mid-Cap Value 7.76%
Small-Cap Growth 8.17%
Small-Cap Value 2.87%
Undetermined 0.07%
 Composition
U.S. Stocks 72.39%   Other 0.07%
Non-U.S. Stocks 27.54%      
The style and sector characteristics of the portfolio are determined as of 07/19/2017 and will likely vary thereafter due to market fluctuations in the underlying securities.  

 Key Stats
Weighted Average Market Cap $46,090.15
Weighted Average Price/Earnings 26.82
Weighted Average Price/Book 5.08
As of 7/19/2017
All market capitalization numbers are in USD$ Millions

 Holdings  Export Current Holdings | View Initial Holdings  
NameSymbolSectorStyleWeighting
 Vertex Pharmaceuticals Incorporated VRTX Health Care  Health Care Large-Cap Growth 6.57%
 Regeneron Pharmaceuticals, Inc. REGN Health Care  Health Care Large-Cap Growth 4.86%
 QIAGEN N.V. QGEN Health Care  Health Care Mid-Cap Value 4.36%
 PRA Health Sciences, Inc. PRAH Health Care  Health Care Mid-Cap Growth 4.30%
 Bio-Techne Corporation TECH Health Care  Health Care Mid-Cap Growth 4.28%
 Thermo Fisher Scientific Inc. TMO Health Care  Health Care Large-Cap Value 4.26%
 Grifols, S.A. (ADR) GRFS Health Care  Health Care Large-Cap Growth 4.22%
 Ligand Pharmaceuticals Inc. (Class B) LGND Health Care  Health Care Small-Cap Growth 4.21%
 AbbVie Inc. ABBV Health Care  Health Care Large-Cap Growth 4.06%
 Amgen Inc. AMGN Health Care  Health Care Large-Cap Growth 4.04%
 Gilead Sciences, Inc. GILD Health Care  Health Care Large-Cap Growth 3.98%
 CSL Limited (ADR) CSLLY Health Care  Health Care Large-Cap Growth 3.98%
 Celgene Corporation CELG Health Care  Health Care Large-Cap Growth 3.96%
 Jazz Pharmaceuticals Plc JAZZ Health Care  Health Care Mid-Cap Growth 3.96%
 China Biologic Products, Inc. CBPO Health Care  Health Care Small-Cap Growth 3.96%
 Alexion Pharmaceuticals, Inc. ALXN Health Care  Health Care Large-Cap Value 3.95%
 Biogen Inc. BIIB Health Care  Health Care Large-Cap Growth 3.81%
 Illumina, Inc. ILMN Health Care  Health Care Large-Cap Growth 3.72%
 Roche Holding AG (ADR) RHHBY Health Care  Health Care Large-Cap Growth 3.67%
 BioMarin Pharmaceutical Inc. BMRN Health Care  Health Care Mid-Cap Growth 3.59%
 Incyte Corporation INCY Health Care  Health Care Large-Cap Growth 3.46%
 United Therapeutics Corporation UTHR Health Care  Health Care Mid-Cap Value 3.40%
 Shire Plc (ADR) SHPG Health Care  Health Care Large-Cap Value 3.39%
 Seattle Genetics, Inc. SGEN Health Care  Health Care Mid-Cap Growth 3.07%
 Acorda Therapeutics, Inc. ACOR Health Care  Health Care Small-Cap Value 2.87%
 
Total Number of Holdings:    25
Underlying Securities information represented above is as of 07/19/2017 but will vary with future fluctuations in the market.

 Deferred Sales Charge Schedule
Amount Date
$0.08160 July 20, 2017
$0.08170 August 18, 2017
$0.08170 September 20, 2017

Risk Considerations

Equity Risk. An investment in a portfolio containing common stocks is subject to certain risks, such as an economic recession and the possible deterioration of either the financial condition of the issuers of the equity securities or the general condition of the stock market.

Sector Concentration Risk. A portfolio which is concentrated in an individual sector is subject to additional risks, including limited diversification.

Biotechnology Risk. The companies engaged in the biotechnology and pharmaceutical sectors are subject to fierce competition, substantial research and development costs, governmental regulations and pricing constraints, and their products and services may be subject to rapid obsolescence. Biotechnology and pharmaceutical stocks have experienced extreme price and volume fluctuations that are often unrelated to their operating performance. In addition, implementation of the Health Care and Education Affordability Reconciliation Act of 2010 continues to have significant implications for companies in the health care sector.

Buy & Hold Risk – Taxable Trusts. This UIT is a buy and hold strategy and investors should consider their ability to hold the trust until maturity. There may be tax consequences unless units are purchased in an IRA or other qualified plan.

Foreign Securities Risk. An investment in securities of foreign issuers should be made with an understanding of the additional risks involved, such as currency fluctuations, political risk, withholding, the lack of adequate financial information, and exchange control restrictions impacting foreign issuers.

Pharmaceutical Risk. The companies engaged in the pharmaceutical sector are subject to fierce competition, substantial research and development costs, governmental regulations, pricing constraints, and their products and services may be subject to rapid obsolescence.

Small-Cap and Mid-Cap Risk. An investment in a portfolio containing small-cap and mid-cap companies is subject to additional risks, as the share prices of small-cap companies and certain mid-cap companies are often more volatile than those of larger companies due to several factors, including limited trading volumes, products, financial resources, management inexperience and less publicly available information.

Volatility Risk. The value of the securities held by the trust may be subject to steep declines or increased volatility due to changes in performance or perception of the issuers.

All data used for the sector and style classification comparisons is from Bloomberg Finance L.P, which we believe to be reliable, but do not take responsibility for its accuracy.

The style and capitalization characteristics used to describe the stocks are designed to help you understand how they fit into your overall investment plan. Due to changes in the value of the stocks the characteristics may vary over time. In general, growth stocks have high relative price-to-book ratios while value stocks have low relative price-to-book ratios. In determining market capitalization characteristics, we analyze the market capitalizations of the 3,000 largest stocks in the U.S. (excluding foreign securities, ADRs, limited partnerships and regulated investment companies) on a monthly basis. Companies with market capitalizations among the largest 10% are considered Large-Cap securities, the next 20% are considered Mid-Cap securities and the remaining securities are considered Small-Cap securities.

You should carefully consider the trust's investment objectives, risks, and charges and expenses before investing. Contact your financial advisor or call First Trust Portfolios, L.P. at 1.800.621.1675 to request a prospectus, which contains this and other information about the trust. Read it carefully before you invest.

This product information does not constitute an offer to sell, or a solicitation of an offer to buy securities in any state to any person to whom it is not lawful to make such an offer. Sales of any of these securities must include prospectus delivery and the services of a retail broker/dealer duly licensed in the appropriate states.

Not FDIC Insured, Not Bank Guaranteed and May Lose Value.

Printer Friendly Page Printer Friendly Page

 
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA and the Internal Revenue Code. First Trust has no knowledge of and has not been provided any information regarding any investor. Financial advisors must determine whether particular investments are appropriate for their clients. First Trust believes the financial advisor is a fiduciary, is capable of evaluating investment risks independently and is responsible for exercising independent judgment with respect to its retirement plan clients.
First Trust Portfolios L.P.  Member SIPC and FINRA.
First Trust Advisors L.P.
Home |  Important Legal Information |  Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2017 All rights reserved.